WuXi AppTec in manufacturing pact with REGENXBIO; China's Bohui buys U.S.-based Advion;

> China's WuXi AppTec ($WX) has signed an exclusive manufacturing pact with U.S.-based gene therapy firm REGENXBIO for a proprietary production process for NAV Technology treatments at WuXi's 145,000-square-foot cGMP facility currently under construction in Philadelphia. Release (PDF)

> France-based Poxel successfully completed a Phase I Type 2 diabetes clinical trial of its Imeglimin candidate in Japan, building on completed Phase II clinical trials in Type 2 diabetes patients in the U.S. and EU. Release

> Glenmark Pharmaceuticals received U.S. FDA ANDA approval for levonorgestrel, used to prevent pregnancy in women who elect to use oral contraceptives. Release (PDF)

> Japan's Taiho Pharmaceutical and France's Servier entered into an exclusive license agreement on June 12, for Europe, as well as unidentified countries, for the development and commercialization of TAS-102 to treat refractory metastatic colorectal cancer. Release

> China's Bohui has bought U.S.-based systems and consumables developer Advion in a deal set to close on June 30, 2015. Release

> Sweden-based NeuroVive Pharmaceutical's Asia unit signed with the South Korean affiliate of Sanofi ($SNY) for an upfront payment, a conditional milestone payment and royalty on potential future sales for the development and commercialization of CicloMulsion, used to treat reperfusion injury in cardiovascular disease, in South Korea. Release

> China's Tianyin Pharmaceutical, which makes Ethical Products and traditional Chinese medicines, has increased its stake in Buchang Pharma to 95%. Release